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Background: Patient with α-Fetoprotein (AFP)-producing gastric cancer usually has a short survival time due to
frequent hepatic and lymph node metastases. Gastric cancer with portal vein tumor thrombus (PVTT) is rare and
has an extremely poor prognosis.
Case presentation: A 63-year-old man was found to have a huge Type 3 gastric cancer with a PVTT and a highly
elevated serum AFP level. Chemotherapy with S-1 plus cisplatin was given to this patient with unresectable gastric
cancer for 4 months. The serum AFP level decreased from 6,160 ng/mL to 60.7 ng/mL with chemotherapy. Since
the PVTT disappeared after the chemotherapy, the patient underwent total gastrectomy. Histological findings of the
primary tumor after chemotherapy showed poorly differentiated adenocarcinoma without hepatoid cells and viable
tumor cells remaining in less than 1/3 of the neoplastic area of mucosa and one lymph node. The cancerous cells were
immunohistochemically stained by anti-AFP antibody. The patient has survived for 48 month without recurrence.
Conclusions: AFP-producing gastric cancer with a PVTT has an extremely poor prognosis, but long-term survival was
achieved for this dismal condition by salvage surgery after chemotherapy.
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α-Fetoprotein-producing gastric cancer (AFP-GC) accounts
for 1.6-4.3% of all gastric cancers and has biological
aggressiveness, with frequent hepatic and lymph node
metastases, resulting in a poor prognosis [1-4]. The mech-
anism of the aggressive behavior of AFP-GC has been
under investigation. Recent molecular biological and
genetic studies of AFP-CG have suggested that its
malignancy is related to high vessel density [5], high
expression of vascular epidermal growth factor (VEGF)
[5], high expression of VEGF-C [6], frequent p53 abnor-
malities [3], high expression of c-Met [7], absence of AT
motif binding factor 1 [8], frequent loss of heterozygosity
[9], and high fractional allelic loss in the tumor cells
[9]. AFP-GC is pathologically divided into 2 types,* Correspondence: bunzo@med.osaka-cu.ac.jp
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unless otherwise stated.hepatoid adenocarcinoma and nonhepatoid adenocar-
cinoma, including poorly/moderately/well-differentiated
adenocarcinoma of common type gastric cancer and enter-
oblastic adenocarcinoma [10,11]. Most tumors have both
hepatoid and non-hepatoid components [10]. Although a
portal vein tumor thrombus (PVTT) occurs frequently
in hepatocellular carcinoma [12], it is rarely observed
in gastric cancer [13]. The data of the 18th follow-up
survey of primary liver cancer by The Liver Cancer Study
Group of Japan demonstrated that 26.1% of 5,368 patients
with Hepatocellular carcinoma (HCC) had microscopic
PVTT [14]. The annual report of the pathological autopsy
cases in Japan showed that PVTT occurred in 1.2% of
patients with gastric cancer [15]. It should be noted here
that PVTT in liver cancer includes tumor thrombus in the
intrahepatic portal vein, whereas PVTT in gastric cancer
usually means thrombus limited to the main trunk or the
first branch of the portal vein. Eom et al. reported that the
median survival of patients with gastric cancer with PVTTThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Endoscopic imaging. (A) Before chemotherapy with S-1 plus cisplatin (B) After 3 courses of chemotherapy.
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reports of salvage surgery after chemotherapy for AFP-
GC in the English literature [17]. A case of AFP-GC
with PVTT who has survived for 48 months without
recurrence after salvage gastrectomy following chemo-
therapy with S-1 plus cisplatin is reported.
Case presentation
A 63-year-old man was investigated for positive fecal
occult blood in February 2010. Gastrointestinal endos-
copy revealed a Type 3 gastric cancer located in the
lesser curvature side and in middle and upper parts of
the stomach. The oral side of the tumor was at 1cm
anal side of esophagogastric junction (Figure 1A). The
pathological diagnosis for biopsy specimens obtained
by endoscopy was poorly differentiated adenocarcinoma
of the stomach. Abdominal computed tomography (CT)
showed a perigastric lymph node (30 mm× 23 mm) and a
PVTT (16 mm× 13 mm). Endoscopic ultrasound was not
performed because the PVTT was enhanced in the CT
(Figure 2A). A PVTT is extremely rare in gastric cancer
and has been reported to be associated with AFP-GC.
Therefore, the serum α-Fetoprotein (AFP) level was
measured and found to be very elevated (6,160 ng/mL).
The patient had no liver diseases, including hepatitis
and hepatocellular carcinoma. Gastric cancer with distant
metastases, including a portal thrombus, has a very poorFigure 2 Abdominal computed tomography imaging. (A) Before chemprognosis and is usually inoperable. This case was treated
with combined chemotherapy of S-1 plus cisplatin, a
standard regimen for unresectable gastric cancer in Japan
[18]. After 3 courses of the regimen, composed of S1
(120 mg/day, orally, days 1-21) and cisplatin (60 mg/m2,
intravenously, day 8) following by 14 days’ rest, the
primary lesion was flattened (Figure 1B), the perigastric
lymph node shrank to 13 mm× 10 mm, and the PVTT
disappeared, allowing curative surgery to be performed
(Figure 2B). The serum AFP level decreased to 60.7 ng/mL.
Total gastrectomy and D2 lymphadenectomy was
performed with the resection of distal esophagus to assure
tumor-free margin. The macroscopic findings of the
resected specimen included a slightly elevated tumor
spreading from the cardia to the gastric body, with dimen-
sions of 52 mm× 48 mm. The pathological diagnosis was
poorly differentiated adenocarcinoma with invasion to the
mucosa and one perigastric lymph node metastasis. No
hepatoid cells were found in the resected specimens. The
pathological staging of the current case was Stage IB, and
the histological evaluation according to the criteria of
tumor response of the Japanese Classification of Gastric
Carcinoma, 3rd English edition [19], after preoperative
therapy was Grade 2 (viable tumor cells remained in less
than 1/3 of the neoplastic area) (Figure 3A). Immunohis-
tochemical staining showed AFP-GC (Figure 3B). S-1 was
given for 12 months by the standard regimen of S-1otherapy with S-1 plus cisplatin (B) After 3 courses of chemotherapy.
Figure 3 Pathological findings. (A) Hematoxylin-eosin staining (magnification X40). (B) Immunohistochemistry using anti-α-fetoprotein antibody.
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14 days’ rest). However, the amount was reduced to 80
mg/day after the second course due to Grade 3 diarrhea.
The patient has been alive without recurrence for 48
months. The serum AFP level became 2.4 ng/mL after the
operation and has continued within the normal limit
(Figure 4).Conclusions
Inoue et al. reported that the 5-year survival rate of their
53-patient series of AFP-GC was 34%, although 53% of
them had synchronous or metachronous hepatic metas-
tases [4]. They suggested that the prognosis of AFP-GC
was not as poor as previously believed, and that multi-
modality treatment may be useful to improve survival.
Adachi et al. analyzed 270 cases of AFP-GC reported in
the Japanese literature from 1982 to 2001, including one
of their patients, and they reported that 5-year survival
rates were 42% and 22%, and the median survival periods
were 29 months and 14 months in patient with curative
gastrectomy and in all patients, respectively [2]. Kochi
et al. reported a significantly better response (70% vs.
31.9%, respectively), and a better conversion to surgery
rate (40% vs. 12.8%) of stage IV AFP-CG by combination
therapy with 5-fluorouracil, leucovorin, etoposide, and
cisplatin was shown compared to Stage IV non-AFP-CG
[17]. The disappearance of PVTT in the current AFP-GCFigure 4 The change in the serum α-fetoprotein value with
salvage surgery following chemotherapy.by chemotherapy with S-1 plus cisplatin conferred operabil-
ity on this case, resulting a long-term tumor-free survival
after the curative operation. Based on the current case and
the previous reports, salvage surgery for AFP-GC should be
done to prolong survival when curative surgery could be
performed after chemotherapy.
The current AFP-GC with PVTT had the elevated
level of serum AFP and the poorly differentiated adeno-
carcinoma cells stained with anti-AFP antibody immu-
nohistochemically. Although the incidence of PVTT in
AFP-GC has not been elucidated, a few reports suggested
a relatively high incidence of PVTT in AFP-GC. Araki
et al. reported that, among four patients with gastric
cancer and PVTT, three patients showed elevated serum
AFP levels, and two patients were proven immunohisto-
chemically to be producing AFP in the primary tumor
[20]. Lee et al. found that 50% (4/8) of hepatoid adeno-
carcinomas of the stomach had PVTT in retrospective
analyses of CT findings [21].
The prognosis of AFP-GC with PVTT has been thought
to be miserable. However, Saitoh et al. [22] reported a
case of AFP-GC with PVTT as a recurrent lesion after
gastrectomy and following various kinds of chemotherapy
for liver and lymph node metastases. The PVTT lesion
showed partial response to irinotecan plus cisplatin as
the 5th line chemotherapy and S-1 monotherapy as the
6th line chemotherapy, and the patient lived for more
than 5 years after the initiation of systemic chemotherapy
against recurrence involving the liver and lymph nodes.
Contrary to the case reported by Saitoh et al, the PVTT
occurred simultaneously with primary tumor and com-
pletely disappeared after chemotherapy in the current
case. Both of the current and their cases demonstrated
that chemotherapies for AFP-GC with PVTT were effect-
ive and contributed to the long survival. Yamaguchi et al.
[23] reported 17 cases of AFP-GC with PVTT through a
literature search from 1980 to 2002, including one of their
own cases. They suggested that complete resection of
AFP-GC with PVTT may lead to long-term survival based
on their analysis of the literature data. The elimination of
PVTT was an important factor for long term survival both
in the current report and the case reported by Yamaguchi
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different: chemotherapy and extirpation, respectively.
Recently, S-1 plus cisplatin for unresectable/recurrent
gastric cancer has been recognized as a standard therapy
in Japan [18]. A few phase II studies of neoadjuvant
chemotherapy with S-1 plus cisplatin for advanced gastric
cancer have been conducted [24,25]. Following the prom-
ising results of these phase II studies, a phase III study
(JCOG0501) of S-1 plus cisplatin as neoadjuvant chemo-
therapy for type 4 and large type 3 gastric cancer has been
ongoing. The current case was expected to have a very
poor prognosis at the time of diagnosis of AFP-GC with
PVTT. However, chemotherapy with S-1 plus cisplatin
was effective to decrease PVTT, and the primary lesion
was curatively resected. This is the first report suggesting
that salvage surgery following chemotherapy may contrib-
ute to curative resection of AFP-GC with PVTT.
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